Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Diagnos Inc V.ADK

Alternate Symbol(s):  DGNOF

Diagnos Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications, such as computer assisted retina analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. It provides software-based services to assist health specialists in the detection of diabetic retinopathy and other eye-related pathologies. Its geographical areas include Canada, the United States of America, Mexico, and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.


TSXV:ADK - Post by User

Bullboard Posts
Post by LannyMcdonaldon Jan 07, 2017 5:22am
262 Views
Post# 25678419

Compliance

ComplianceDespite the high level of clinical efficacy and cost effectiveness of DR screening and treatment..problems remain with screening and treatment COMPLIANCE.Many people with diabetes do not access regular eye examinations and the barriers that prevent them from attending for screening are numerousFactors affecting nonadherence to recommended guidelines are numerous.They include lack of awareness that DR can lead to blindness or that severe retinopathy can be asymptomaticLimited access to eye care professionals, particularly in remote areasEnter Diagnos.CARA is a tele-ophthalmology platform which combines advanced retinal imaging with clinical image interpretation services performed by a network of ophthalmologists. CARA is a turnkey solution for primary care physicians allowing their patients to benefit from a remote ophthalmology consultation..COMPLIANCE will ultimately get better when Governments give the green light to installing the CARA systems in walk-in clinics or Pharmacies.DIAGNOS appears to be the front runner in this technology.
Bullboard Posts